Analysts think AXSM stock price could increase by 64%
Jun 09, 2025, 11:25 AM
-5.74%
What does AXSM do
Axsome Therapeutics, based in New York City, develops therapies for central nervous system disorders, with commercial products Auvelity and Sunosi, and investigational drugs AXS-05 and AXS-07. The company employs 545 staff and went public in November 2015.
19 analysts think AXSM stock price will increase by 64.13%. The current median analyst target is $183.60 compared to a current stock price of $111.86. The lowest analysts target is $147.46 and the highest analyst target is $220.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
